Sigilon Therapeutics (SGTX) Short Interest Ratio & Short Volume Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Sigilon Therapeutics Short Interest DataSigilon Therapeutics (SGTX) has a short interest of 8,200 shares, representing 0.58% of the float (the number of shares available for trading by the public). This marks a -18.81% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 62,902 shares to cover all short positions.Current Short Interest8,200 sharesPrevious Short Interest10,100 sharesChange Vs. Previous Month-18.81%Dollar Volume Sold Short$171,544.00Short Interest Ratio0.1 Days to CoverLast Record DateJuly 31, 2023Outstanding Shares2,510,000 sharesFloat Size1,420,000 sharesShort Percent of Float0.58%Today's Trading Volume83,600 sharesAverage Trading Volume62,902 sharesToday's Volume Vs. Average133% Short Selling Sigilon Therapeutics? Sign up to receive the latest short interest report for Sigilon Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSGTX Short Interest Over TimeSGTX Days to Cover Over TimeSGTX Percentage of Float Shorted Over Time Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Sigilon Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/20238,200 shares $171,544.00 -18.8%0.6%0.1 $20.92 7/15/202310,100 shares $214,625.00 -1.0%0.7%0.1 $21.25 6/30/202310,200 shares $229,602.00 +7.4%0.7%0.1 $22.51 6/15/20239,500 shares $48,070.00 +6.7%0.7%1.2 $5.06 5/31/20238,900 shares $37,380.00 -15.2%0.6%0.6 $4.20 5/15/202310,500 shares $69,464.85 -93.3%N/A0.6 $6.62 Get the Latest News and Ratings for SGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/30/2023156,600 shares $114,318.00 +21.8%1.1%0.8 $0.73 4/15/2023128,600 shares $83,590.00 -5.8%0.9%0.6 $0.65 3/31/2023136,500 shares $126,958.65 -26.1%1.0%0.3 $0.93 3/15/2023184,600 shares $210,444.00 -24.9%1.3%0.5 $1.14 2/28/2023245,700 shares $267,813.00 +13.4%1.8%0.9 $1.09 2/15/2023216,700 shares $166,859.00 -5.6%1.0%0.9 $0.77 1/31/2023229,500 shares $166,066.20 +46.9%1.1%1 $0.72 1/15/2023156,200 shares $71,852.00 -5.1%0.7%0.7 $0.46 12/30/2022164,500 shares $57,575.00 -7.0%0.8%3.5 $0.35 12/15/2022176,800 shares $58,344.00 +11.8%0.9%3.7 $0.33 11/30/2022158,200 shares $62,394.08 +6.3%0.8%3.4 $0.39 11/15/2022148,800 shares $67,852.80 -5.9%0.8%3.6 $0.46 10/31/2022158,200 shares $79,416.40 +25.4%1.1%4.1 $0.50 10/15/2022126,200 shares $61,838.00 -9.7%0.9%3.1 $0.49 9/30/2022139,700 shares $70,548.50 -5.7%1.0%3.1 $0.51 9/15/2022148,200 shares $100,776.00 +6.5%1.0%2 $0.68 8/31/2022139,200 shares $86,526.72 +7.7%1.0%1.6 $0.62 8/15/2022129,300 shares $93,108.93 -9.6%0.9%1.3 $0.72 7/31/2022143,100 shares $101,601.00 +9.9%1.0%1.3 $0.71 7/15/2022130,200 shares $108,586.80 -17.3%0.9%1.1 $0.83 6/30/2022157,400 shares $130,642.00 -73.9%1.1%1.3 $0.83 6/15/2022603,300 shares $552,019.50 -9.2%4.3%5 $0.92 5/31/2022664,500 shares $503,691.00 +25.2%4.7%6.7 $0.76 5/15/2022530,600 shares $398,480.60 +11.6%3.7%5.9 $0.75 4/30/2022475,600 shares $499,380.00 +5.5%3.4%5.5 $1.05 4/15/2022450,800 shares $635,628.00 -4.1%3.2%5.1 $1.41 3/31/2022469,900 shares $690,753.00 +15.7%3.3%4.9 $1.47 3/15/2022406,200 shares $548,370.00 +13.3%2.9%3.9 $1.35 2/28/2022358,500 shares $519,825.00 +11.5%2.5%3 $1.45 2/15/2022321,500 shares $524,045.00 +31.8%2.3%2.3 $1.63 1/31/2022244,000 shares $475,800.00 +9.7%1.7%1.7 $1.95 1/15/2022222,400 shares $489,280.00 -4.7%1.6%1.5 $2.20 12/31/2021233,400 shares $644,184.00 -3.7%1.7%1.7 $2.76 12/15/2021242,400 shares $625,392.00 -15.5%1.7%1.8 $2.58Trump’s weapon lurks in abandoned America (Ad)Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary 11/30/2021286,700 shares $1.08 million -31.7%2.1%2.2 $3.76 11/15/2021419,900 shares $2.14 million -37.0%3.0%2.9 $5.09 10/29/2021666,000 shares $3.59 million +7.0%4.8%4.1 $5.39 10/15/2021622,400 shares $3.45 million -19.9%4.5%3.5 $5.55 9/30/2021777,400 shares $4.39 million +1.0%5.6%3.7 $5.65 9/15/2021769,400 shares $4.42 million -6.9%5.5%2.9 $5.75 8/31/2021826,800 shares $4.91 million +6.7%6.1%2.9 $5.94 8/13/2021775,000 shares $4.12 million -3.4%5.7%2.8 $5.32 7/30/2021802,400 shares $4.04 million -18.7%6.0%3.2 $5.04 7/15/2021987,000 shares $5.93 million +54.0%7.4%4.4 $6.01 6/30/2021641,000 shares $6.88 million +76.3%4.8%3.2 $10.73 6/15/2021363,500 shares $3.74 million -25.2%2.7%2.6 $10.29 5/28/2021485,900 shares $5.67 million -1.7%3.6%4 $11.67 5/14/2021494,500 shares $6.55 million +9.9%3.7%4.5 $13.25 4/30/2021450,100 shares $6.63 million -14.9%3.4%3.7 $14.74 4/15/2021528,700 shares $10.51 million -7.4%4.0%4.3 $19.88 3/31/2021571,000 shares $10.71 million +176.8%4.6%4.4 $18.76 3/15/2021206,300 shares $6.01 million +60.7%1.7%1.5 $29.15 2/26/2021128,400 shares $3.51 million +46.4%1.1%0.8 $27.32 2/12/202187,700 shares $3.49 million +49.2%0.7%0.5 $39.81 1/29/202158,800 shares $1.81 million +25.6%0.5%0.3 $30.74 1/15/202146,800 shares $1.60 million No Change0.4%0.2 $34.16 SGTX Short Interest - Frequently Asked Questions What is Sigilon Therapeutics' current short interest? Short interest is the volume of Sigilon Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 8,200 shares of SGTX short. 0.58% of Sigilon Therapeutics' shares are currently sold short. Learn More on Sigilon Therapeutics' current short interest. What is a good short interest percentage for Sigilon Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.58% of Sigilon Therapeutics' floating shares are currently sold short. Is Sigilon Therapeutics' short interest increasing or decreasing? Sigilon Therapeutics saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 8,200 shares, a decline of 18.8% from the previous total of 10,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Sigilon Therapeutics' float size? Sigilon Therapeutics currently has issued a total of 2,510,000 shares. Some of Sigilon Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sigilon Therapeutics currently has a public float of 1,420,000 shares. How does Sigilon Therapeutics' short interest compare to its competitors? 0.58% of Sigilon Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Sigilon Therapeutics: RedHill Biopharma Ltd. (1.71%), Pyxis Oncology, Inc. (8.68%), MacroGenics, Inc. (10.69%), Atai Life Sciences (8.18%), Immutep Limited (4.16%), Gossamer Bio, Inc. (4.23%), Trevi Therapeutics, Inc. (2.07%), XBiotech Inc. (4.58%), Rezolute, Inc. (3.29%), Mersana Therapeutics, Inc. (6.94%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.34 billion), Occidental Petroleum Co. ($2.88 billion), Coinbase Global, Inc. ($2.50 billion), Rivian Automotive, Inc. ($2.47 billion), Palantir Technologies Inc. ($2.37 billion), Royal Caribbean Cruises Ltd. ($2.33 billion), T. Rowe Price Group, Inc. ($2.29 billion), Tractor Supply ($1.59 billion), Upstart Holdings, Inc. ($1.58 billion), and Enphase Energy, Inc. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Sigilon Therapeutics stock? Short selling SGTX is an investing strategy that aims to generate trading profit from Sigilon Therapeutics as its price is falling. SGTX shares are trading down $0.59 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sigilon Therapeutics? A short squeeze for Sigilon Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SGTX, which in turn drives the price of the stock up even further. How often is Sigilon Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SGTX, twice per month. The most recent reporting period available is July, 31 2023. More Short Interest Resources from MarketBeat Related Companies: RedHill Biopharma Short Interest Data Pyxis Oncology Short Interest Data MacroGenics Short Interest Data Atai Life Sciences Short Interest Data Immutep Short Interest Data Gossamer Bio Short Interest Data Trevi Therapeutics Short Interest Data XBiotech Short Interest Data Rezolute Short Interest Data Mersana Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SGTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigilon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigilon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.